Patents by Inventor Darcy Bates

Darcy Bates has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination treatment protocol
    Patent number: 10137105
    Abstract: The present disclosure provides a combination and a method for treating chronic lymphocytic leukemia (CLL).
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: November 27, 2018
    Assignee: Bionomics Limited
    Inventors: Alan R. Eastman, Darcy Bates, Gabriel Kremmidiotis
  • Method for treating chronic lymphocytic leukemia
    Patent number: 9987293
    Abstract: The present disclosure provides methods for treating chronic lymphocytic leukemia (CLL) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of formula (I) or a salt, solvate or prodrug thereof. Specific compounds of the invention include 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran which is also known as BNC105 and disodium 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate which is also known as BNC 105P.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: June 5, 2018
    Assignee: BIONOMICS LIMITED
    Inventors: Alan R. Eastman, Darcy Bates
  • COMBINATION TREATMENT PROTOCOL
    Publication number: 20180042887
    Abstract: The present disclosure provides a combination and a method for treating chronic lymphocytic leukemia (CLL).
    Type: Application
    Filed: March 2, 2016
    Publication date: February 15, 2018
    Applicant: Bionomics Limited
    Inventors: Alan R. Eastman, Darcy Bates, Gabriel Kremmidiotis
  • METHOD FOR TREATING CHRONIC LYMPHOCYTIC LEUKEMIA
    Publication number: 20170112862
    Abstract: The present disclosure provides methods for treating chronic lymphocytic leukemia (CLL) with medicaments useful for same. The medicaments can be pharmaceutical compositions or kits comprising compounds of formula (I) or a salt, solvate or prodrug thereof. Specific compounds of the invention include 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran which is also known as BNC105 and disodium 6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzofuran-7-yl phosphate which is also known as BNC 105P.
    Type: Application
    Filed: April 4, 2014
    Publication date: April 27, 2017
    Inventors: Alan R. Eastman, Darcy Bates